December 17, 2020
IPOPI attends virtual RECOMB meeting
Each year the partners of the RECOMB research project come together to discuss the progress made during the past year. This year’s meeting was initially scheduled to take place in Leiden (the Netherlands) in April 2020 but was postponed to November and moved online due to the COVID-19 pandemic.
The well attended meeting brought together more than 45 participants, representing most of the partners, to discuss the progress made by the different working groups. Despite some delays due to the pandemic, many partners had made important progress for the project. The meeting also made room for discussions of challenges and potential solutions encountered since the last meeting in 2019.
IPOPI, represented by IPOPI’s President Martine Pergent, Executive Director Johan Prevot and NMO Programmes Officer Julia Nordin, informed the partners about the progress made in terms of dissemination and exploitation, the work package where IPOPI is the leading partner. We also presented the suggested deliverables on the horizon for 2021, which were all well received by the partners.
RECOMB is a project funded by one of the research programmes the European Commission has made available to researchers in Europe (European Union’s Horizon 2020 research and innovation programme). The aim of RECOMB is to create a novel treatment for RAG1-SCID by performing phase 1 and phase 2 clinical trials using autologous haematopoietic stem cell‒based gene therapy.
More information on the RECOMB project can be found here: www.recomb.eu
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 755170 (RECOMB).